drugset / Trial / NCT05584137
Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is a phase II study to evaluate the efficacy, safety and tolerability of HLX26 and HLX10 in the treatment of patients with metastatic colorectal carcinoma that had received 3 prior therapies.
Timeline
- Start
- 2023-06-15
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
Outcome
Outcome not reported
Stopped (Enrollment): “Due to poor clinical trial accrual, the study was terminated.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX26 | Monoclonal antibody | 500 mg | Intravenous |
| Subject | HLX26 | Monoclonal antibody | 800 mg | Intravenous |
| Subject | HLX26 | Monoclonal antibody | 1600 mg | Intravenous |
| Subject | Serplulimab | Monoclonal antibody | 300 mg | Intravenous |